VANCOUVER, BRITISH COLUMBIA - Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, announced immediate changes to its Board of Directors. Janusz Grabski has resigned from the board, and Thomas Mehrling, M.D., Ph.D., who serves as the company's Chief Executive Officer, has been formally appointed as a director. This appointment is made pursuant to the board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG, as detailed in the company's strategic acquisition announcement.
The company stated that these changes are intended to ensure the board continues to meet Helix's evolving governance and capital markets requirements, and that it has the composition and experience needed to support the company's clinical development and broader corporate objectives. The board expressed gratitude to Mr. Grabski for his service and contributions, wishing him success in his future endeavors.
Helix BioPharma is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. Its pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.
The appointment of the CEO to the board, coupled with the resignation of a long-standing member, signals a strategic alignment of leadership with the company's operational focus. This move may be seen as a step to streamline decision-making and ensure that the board has direct insight into the company's day-to-day activities and strategic direction. For shareholders and investors, this change could indicate a tighter integration between management and governance, potentially leading to more agile responses to clinical and market developments.
Helix BioPharma's common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). The company's commitment to addressing difficult-to-treat cancers remains central to its mission, and these board changes are likely to support its ongoing clinical programs and future growth.
The board changes come at a crucial time for the company, as it continues to advance its pipeline and navigate the complexities of clinical development. With the CEO now on the board, the company may benefit from a more unified approach to governance and strategy. This development is important for stakeholders as it reflects Helix's dedication to maintaining a governance structure that aligns with its evolving needs and capital markets requirements.
